Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Enanta Pharmaceuticals Reported New Preclinical Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at EASL International Liver Congress; CEO Said Data Strongly Support the Continued Development of EDP-721

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today reported new preclinical data for EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for HBV.

ENTA